# US 2025/0084066 A1 · Near-infrared cyanine dyes and conjugates thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084066 A1
- Document ID: US20250084066A1
- Status: Published application
- Kind: A1
- Application number: 18/958,122
- Filed: 2024-11-25
- Published: 2025-03-13
- Earliest claimed: 2020-06-23
- Assignees: Bracco Imaging S.P.A.
- Applicants: Bracco Imaging S.P.A.
- Inventors: Francesco BLASI; Federica BUONSANTI; Federico CRIVELLIN; Andrea FERRARIS; Laura ORIO; Lorena PIZZUTO; Roberta NAPOLITANO; Giovanni VALBUSA
- Web page: https://patentgrep.com/patent/US20250084066A1

## CPC

- C07D 403/10: linked by a carbon chain containing aromatic rings
- A61K 49/0032: {Methine dyes, e.g. cyanine dyes}
- A61K 49/0052: {Small organic molecules (oligomers, polymers, dendrimers A61K49/0054)}
- A61K 49/0056: {Peptides, proteins, polyamino acids}
- C07D 403/14: containing three or more hetero rings
- C09B 23/0066: {the polymethine chain being part of a carbocyclic ring,(e.g. benzene, naphtalene, cyclohexene, cyclobutenene-quadratic acid)}
- C09B 23/0075: {the polymethine chain being part of an heterocyclic ring}
- G01N 33/582: {with fluorescent label}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to the field of optical imaging. More particularly, it relates to compounds of the cyanine family with near-infrared emission characterized by improved physico-chemical and biological properties and to conjugates with biological ligands thereof. The invention also relates to the use of these compounds as optical diagnostic agents in imaging or therapy of solid tumors, to the methods for their preparation and to the compositions comprising them.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

A compound of formula (II)
wherein
X is direct bond or —O—;
Y is a group selected from linear or branched C1-C6 alkyl, C3-C7 cycloalkyl and heterocyclyl, substituted by at least two hydroxyl groups;
R1 is linear or branched C1-C6 alkyl substituted by a group selected from —SO3H, —COOH, —CONH2 and —COO—C1-C6 alkyl;
R4 is linear or branched C1-C6 alkyl substituted by a group selected from —SO3H, —COOH and —CONH—(S)m-T, wherein
S is a spacer;
T is a moiety targeting prostate-specific membrane antigen (PSMA); and
m is an integer equal to 0 or 1; and
R5 is selected from hydrogen, —SO3H, a linear or branched C1-C6 alkyl substituted by —COOH and —CONH—Y, wherein Y is as defined above;
or a stereoisomer or pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 16)

The compound of formula (II) according to claim 16 wherein Y is selected from the group consisting of

### Claim 18 (depends on 16)

The compound of formula (II) according to claim 16, wherein m is an integer equal to 0.

### Claim 19 (depends on 16)

The compound of formula (II) according to claim 16, wherein S is selected from —(CH2)pCOO—, —(CH2CH2O)pCH2CH2COO—and —(CH2CH2O)pCH2CH2NH—, wherein p is an integer between 0 and 20.

### Claim 20 (depends on 16)

The compound of formula (II) according to claim 16, wherein T is glutamic acid-urea-lysine or glutamic acid-urea-lysine-(3-(2-naphtyl)-alanine)-tranexamic acid.

### Claim 21 (depends on 16)

The compound of formula (II) according to claim 16, represented by the formula (IIa)
wherein R1, R4, R5 and X are as defined in claim 16.

### Claim 22 (depends on 16)

The compound of formula (II) according to claim 16 which is selected from

### Claim 23 (depends on 16)

A method of biomedical optical imaging comprising:
contacting cells or tissues of a mammal with the compound as defined in claim 16;
irradiating the cells or tissues at a wavelength absorbed by the compound; and
detecting the near-infrared emission using a fluorescence camera.

### Claim 24 (depends on 23)

The method according to claim 23 wherein the biomedical optical imaging is selected from the group consisting of angiography, perfusion imaging, bile duct imaging and nerve imaging.

### Claim 25 (depends on 23)

The method according to claim 23, further comprising demarcating a tumor margin.

### Claim 26 (depends on 16)

A pharmaceutical diagnostic composition comprising a compound as defined in claim 16 and at least one pharmaceutically acceptable carrier or excipient.

### Claim 27 (depends on 16)

A diagnostic kit comprising at least one compound as defined in claim 16 together with one or more adjuvants.
